Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. NeuroFrontiers

The ARIA Toolkit: A Welcome from the Chair

ReachMD Healthcare Image
Restart
Resume

Subtitles available:  Chinese (simplified), French, German & more

Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    This program provides an interdisciplinary curriculum designed to enhance the management of Amyloid-Related Imaging Abnormalities (ARIA) among key specialties, including neurology, psychiatry, radiology, emergency medicine, and primary care. As novel anti-amyloid beta monoclonal antibodies like lecanemab and donanemab gain FDA approval, understanding ARIA's adverse effects becomes increasingly critical. The program emphasizes teamwork, communication, and tailored education to address the persistent challenges in ARIA recognition and management, ultimately aiming to optimize Alzheimer’s treatment. Through diverse, interactive educational activities, clinicians will improve their diagnostic and management skills, ensuring comprehensive and effective patient care.

  • Provider(s)/Educational Partner(s)

    This curriculum is jointly provided by Medical Education Resources (MER) and Efficient LLC.

  • Commercial Support

    This curriculum is supported by an educational grant from Lilly.

Recommended
Details
Presenters
Comments
  • Overview

    This program provides an interdisciplinary curriculum designed to enhance the management of Amyloid-Related Imaging Abnormalities (ARIA) among key specialties, including neurology, psychiatry, radiology, emergency medicine, and primary care. As novel anti-amyloid beta monoclonal antibodies like lecanemab and donanemab gain FDA approval, understanding ARIA's adverse effects becomes increasingly critical. The program emphasizes teamwork, communication, and tailored education to address the persistent challenges in ARIA recognition and management, ultimately aiming to optimize Alzheimer’s treatment. Through diverse, interactive educational activities, clinicians will improve their diagnostic and management skills, ensuring comprehensive and effective patient care.

  • Provider(s)/Educational Partner(s)

    This curriculum is jointly provided by Medical Education Resources (MER) and Efficient LLC.

  • Commercial Support

    This curriculum is supported by an educational grant from Lilly.

Schedule14 Oct 2024